Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Dose Escalation, Schedule Comparison Study to Evaluate the Safety, Pharmacokinetics, and Viral Kinetics of ABX464 in Untreated Patients With HIV Infection in Mauritius

NCT02452242 is registered in ClinicalTrials.gov with Abivax S.A. as lead sponsor.

NCT NCT02452242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02452242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Dose Escalation, Schedule Comparison Study to Evaluate the Safety, Pharmacokinetics, and Viral Kinetics of ABX464 in Untreated Patients With HIV Infection in Mauritius
Lead sponsor
Abivax S.A.
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2015
Completion date
May 31, 2016
Enrollment
70 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

human immunodeficiency virus infections